WHO Drug Information Vol. 25, No. 2, 2011

More documents

Recommendations

Info

Proposed INN: List 105 WHO Drug Information Vol. 25, No. 2, 2011ficlatuzumabinmunoglobulina G1-kappa, anti-[HGF de Homo sapiens (factor decrecimiento del hepatocito, factor dispersante, SF, hepatopoyetinaA)], anticuerpo monoclonal humanizado;cadena pesada gamma1 (1-448) [VH humanizada (Homo sapiensIGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01 V124>L (114)) [8.8.11](1-118) -Homo sapiens IGHG1*03 (119-448)], (221-214')-disulfurocon la cadena ligera kappa (1'-214') [V-KAPPA humanizada (Homosapiens IGKV4-1*01 (73.30%) -IGKJ2*01) [6.3.9] (1'-107') -Homosapiens IGKC*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuroinmunomodulador, antineoplásico1174900-84-5Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQPGAE VKKPGTSVKL SCKASGYTFT TYWMHWVRQA PGQGLEWIGE 50INPTNGHTNY NQKFQGRATL TVDKSTSTAY MELSSLRSED TAVYYCARNY 100VGSIFDYWGQ GTLLTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448Light chain / Chaîne légère / Cadena ligeraDIVMTQSPDS LAMSLGERVT LNCKASENVV SYVSWYQQKP GQSPKLLIYG 50ASNRESGVPD RFSGSGSATD FTLTISSVQA EDVADYHCGQ SYNYPYTFGQ 100GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 145-201 262-322 368-42622''-96'' 145''-201'' 262''-322'' 368''-426''Intra-L 23'-88' 134'-194'23'''-88''' 134'''-194'''Inter-H-L 221-214' 221''-214'''Inter-H-H 227-227'' 230-230''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación298, 298''galeteronumgaleteronegalétéronegaleterona17-(1H-benzimidazol-1-yl)androsta-5,16-dien-3β-olantiandrogen17-(1H-benzimidazol-1-yl)androsta-5,16-dién-3β-olantiandrogène17-(1H-benzoimidazol-1-il)androsta-5,16-dien-3β-olantiandrógenoC 26 H 32 N 2 O 851983-85-2NCHN 3CH 3HHOHHH172
WHO Drug Information Vol. 25, No. 2, 2011 Proposed INN: List 105ganetespibumganetespibganétespibganetespib5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1H-indol-5-yl)-2,4-dihydro-3H-1,2,4-triazol-3-oneantineoplastic5-[2,4-dihydroxy-5-(propan-2-yl)phényl]-4-(1-méthyl-1H-indol-5-yl)-2,4-dihydro-3H-1,2,4-triazol-3-oneantinéoplasique5-[2,4-dihidroxi-5-(propan-2-il)fenil]-4-(1-metil-1H-indol-5-il)-2,4-dihidro-3H-1,2,4-triazol-3-onaantineoplásicoC 20 H 20 N 4 O 3 888216-25-9H 3 CNOH 3 CCH 3NNHNHOOHindatuximabum ravtansinum #indatuximab ravtansineindatuximab ravtansineimmunoglobulin G4-kappa, anti-[Homo sapiens SDC1 (syndecan-1,CD138)], chimeric monoclonal antibody conjugated to maytansinoidDM4;gamma4 heavy chain (1-449) [Mus musculus VH (IGHV1-9*01 -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo sapiens IGHG4*01 (123-449)], (136-214')-disulfide with kappa light chain (1'-214') [Musmusculus V-KAPPA (IGKV10-94*01 -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (228-228'':231-231'')-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, tomaytansinoid DM4 [N 2' -deacetyl-N 2' -(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker[N-succinimidyl 4-(2-pyridyldithio)butanoate]For the ravtansine part, please refer to the document "INN forpharmaceutical substances: Names for radicals, groups and others"*immunomodulator, antineoplasticimmunoglobuline G4-kappa, anti-[Homo sapiens SDC1 (syndecan-1,CD138)], anticorps monoclonal chimérique conjugué aumaytansinoïde DM4;chaîne lourde gamma4 (1-449) [Mus musculus VH (IGHV1-9*01 -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo sapiens IGHG4*01 (123-449)], (136-214')-disulfure avec la chaîne légère kappa (1'-214')[Mus musculus V-KAPPA (IGKV10-94*01 -IGKJ1*01) [6.3.9] (1'-107')-Homo sapiens IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, aumaytansinoïde DM4 [N 2' -déacétyl-N 2' -(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible[4-(2-pyridyldithio)butanoate de N-succinimidyle]Pour la partie ravtansine, veuillez vous référer au document "INN forpharmaceutical substances: Names for radicals, groups andothers"*.immunomodulateur, antinéoplasique173
Page 1 and 2:
WHO Drug Information Vol. 25, No. 2
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24: WHO Drug Information Vol. 25, No. 2
Page 73: WHO Drug Information Vol. 25, No. 2
show all

WHO Drug Information Vol. 25, No. 2, 2011

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?